Hepatocellular Carcinoma Resectable
Conditions
Brief summary
This study will conduct a prospective cohort study to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurrence, verify whether ctDNA-MRD longitudinal monitoring model can indicate recurrence earlier than imaging examination, and explore the feasibility of guiding adjuvant therapy after curative treatment based on this model.
Detailed description
The recurrence rate of hepatocellular carcinoma after curative treatment is high, and the minimal residual disease(MRD) in patients is the major cause of liver cancer recurrence, and the MRD is an important basis for the decision of adjuvant therapy after curative treatment. Previous studies have confirmed that circulating tumor DNA(ctDNA)-MRD monitoring model can accurately predict the recurrence of hepatocellular carcinoma patients. It was also found in retrospective analysis that tumor free survival was significantly prolonged after ctDNA-positive treatment for hepatocellular carcinoma after resection. This study will conduct a prospective cohort study to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurrence, verify whether ctDNA-MRD longitudinal monitoring model can indicate recurrence earlier than imaging examination, and explore the feasibility of guiding adjuvant therapy after curative treatment based on this model.This study is to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurrence.
Interventions
DIAGNOSTIC_TESTcirculating tumor DNA
blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma
Sponsors
Zhujiang Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female patients aged 18-75 years; 2. Preoperative imaging examination diagnosed hepatocellular carcinoma (BCLC) stage 0 / stage A/stage B, eligible for radical surgery; 3. ECOG physical status score is 0-1; 4. Child-Pugh score is 5-6 points (Level A); 5. Not received any anti-tumor therapy; 6. Laboratory tests were at normal levels within 7 days before enrollment.
Exclusion criteria
1. Patient can't provide blood samples for ctDNA testing; 2. Patient with two or more types of tumors at the same time; 3. Non-primary liver lesions; 4. Pregnant or lactating women; 5. Patient with a history of other malignant tumors within the past 5 years or at the same time, except cured skin basal cell carcinoma, cervical carcinoma in situ and thyroid papillary carcinoma; 6. Patient with serious heart disease; 7. Other conditions deemed unsuitable for inclusion by the researcher.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 2-year recurrence-free survival rate | 2 years | percentage of recurrence-free survival 2 years after surgery |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between ctDNA-MRD status dynamic changes and relapse | 2 years | Correlation between ctDNA-MRD status dynamic changes and relapse |
Countries
China
Contacts
CONTACTMingxin Pan, Prof.
CONTACTCheng Zhang
PRINCIPAL_INVESTIGATORMingxin Pan
Southern Medical University
Outcome results
None listed